A possible opening for peptides in Washington
Weekly Research Update · October 12, 2026
A POSSIBLE OPENING FOR PEPTIDES IN WASHINGTON
This was a big week for peptide news. Reports point to a possible policy shift in D.C., a drugmaker is cracking down on unofficial sellers, and a new lab study is getting attention. Here's what happened, in plain terms.
The Administration May Ease Up on Some Peptides, For Now
The Washington Post reported on October 7 that the Trump administration is drafting a temporary plan. It would let some compounding pharmacies (pharmacies that custom-mix medications) dispense certain peptides that were previously restricted, while longer-term rules are worked out. The report is based on two anonymous sources.
The Alliance for Pharmacy Compounding, led by CEO Scott Brunner, has pushed for this approach, with patient disclosures, side-effect reporting and data collection built in. Pink Sheet reported that some FDA drug-review staff objected internally, citing limited safety data.
It isn't clear yet which peptides would be included or when. The plan is tied to an FDA advisory panel review from July that looked at compounds like BPC-157, TB-500, MOTS-c and Semax. Nothing has been announced and the plan could change. It would not legalize or approve any peptide, and any flexibility would be limited, conditional and reversible.
ALSO THIS WEEK
Lawsuits, stem-cell clinics and an SS-31 study
Lilly widens its legal fight over retatrutide. BioPharma Dive, Bloomberg Law and The Washington Post report that Eli Lilly has sued about five more sellers of unofficial retatrutide, adding to the cases it filed in August, and some of the sellers label their products for research use only. Lilly is also referring cases to the FDA, the Justice Department and state attorneys general. Retatrutide is still in development, and Lilly plans to file for approval in 2027.
Stem-cell clinics are watching closely. STAT reports that regenerative-medicine advocates at the PepMed 2026 conference hope the peptide review could become a model for similar flexibility in their field. The FDA has taken no action on this.
SS-31 in a mouse fertility study. A new paper in Aging Cell found that SS-31 (elamipretide) improved egg quality, fertilization and litter size in older mice, with some limited lab work on human eggs. This is early animal research only. Elamipretide's only approval is an accelerated approval for Barth syndrome, a rare genetic condition.
That's the week. We'll keep watching for official word from the FDA and share what's confirmed as soon as we know. Thanks for reading. — The Palm Beach Vitality Team
READ MORE
The Washington Post (Oct 7, 2026): Trump administration paving way for temporary sale of some unapproved peptides
Palm Beach Vitality shop
https://palmbeach-vitality.store/shop/
Contact us
https://palmbeach-vitality.store/contact/
All products are intended strictly for research use only. Not for human consumption, diagnostic, or therapeutic purposes.